Getting the balance right: Established and emerging therapies for major depressive disorders

References

• PrattLABrodyDJDepression in the United States household population, 2005–2006NCHS Data Brief200871819389321
   PubMedGoogle Scholar
• KesslerRCBerglundPDemlerOThe epidemology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R)JAMA2003289233095310512813115
   PubMed Web of Science ®Google Scholar
• EbmeierKPDonagheyJCSteeleJDRecent developments and current controversies in depressionLancet2006367950515316716413879
   PubMed Web of Science ®Google Scholar
• NIH Consensus ConferenceDiagnosis and treatment of depression in late lifeJAMA19922688101810241501308
   PubMed Web of Science ®Google Scholar
• RothschildAJThe diagnosis and treatment of late-life depressionJ Clin Psychiatry19965755118647792
   PubMed Web of Science ®Google Scholar
• SteffensDCSkoogINortonMCPrevalence of depression and its treatment in an eldery population: The Cache County studyArch Gen Psychiatry200057660160710839339
   PubMed Web of Science ®Google Scholar
• BelmakerRHAgamGMajor depressive disorder: Mechanisms of diseaseN Engl J Med20083581556818172175
   PubMed Web of Science ®Google Scholar
• JainRThe implication of pain and physical symptoms in depressionJ Clin Psychiatry2009706e1919573475
   PubMedGoogle Scholar
• aan het RotMMathewSJCharneyDSNeurobiological mechanisms in major depressive disorderCMAJ2009180330531319188629
   PubMed Web of Science ®Google Scholar
• CaspiASugdenKMoffittTEInfluence of life stress on depression: Moderation by a polymorphism in the 5-HTT geneScience2003301563138638912869766
   PubMed Web of Science ®Google Scholar
• HansenneMBianchiJEmotional intelligence and personality in major depression: Trait versus state effectsPsychiatry Res20091661636819193446
   PubMed Web of Science ®Google Scholar
• ZhangXGainetdinovRRBeaullieuJMLoss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depressionNeuron2005451111615629698
   PubMed Web of Science ®Google Scholar
• PitchotWHansenneMPintoEReggersJFuchsSAnsseauM5-Hydroxytryptamine 1A receptor, major depression, and suicidal behaviorBiol Psychiatry2005581185485816139805
   PubMed Web of Science ®Google Scholar
• SvenningsonPCherguiKRachleffIAlterations in 5-HT1B receptor function by p11 in depression-like statesScience20063115757778016400147
   PubMed Web of Science ®Google Scholar
• OrdwayGASchenkJStockmeierCAMayWKlimekVElevated agonist binding to alpha 2-adrenoceptors in the locus coeruleus in major depressionBiol Psychiatry200353431532312586450
   PubMed Web of Science ®Google Scholar
• CouplandNJOgilvieCJHegadorenKMSeresPHanstockCCAllenPSDecreased prefrontal myo-inositol in major depressive disorderBiol Psychiatry200557121526153415953489
   PubMed Web of Science ®Google Scholar
• ValdizanEMGutierrezOPazosAAdenylate cyclase activity in post-mortem brain of suicide subjects: Reduced response to beta-adrenergic stimulationBiol Psychiatry200354121457146414675811
   PubMed Web of Science ®Google Scholar
• BlendyJAThe role of CREB in depression and antidepressant treatmentBiol Psychiatry200659121144115016457782
   PubMed Web of Science ®Google Scholar
• MannJJThe medical management of depressionN Engl J Med2005353171819183416251538
   PubMed Web of Science ®Google Scholar
• VreeburgSAHoogendijkWJvan PeltJMajor depressive disorder and hypothalamic-pituitary-adrenal axis activity: Results from a large cohort studyArch Gen Psychiatry200966661762619487626
   PubMed Web of Science ®Google Scholar
• BurkeHMDavisMCOtteCMohrDCDepression and cortisol responses to psychological stress: A meta-analysisPsychoneuroendocrinology200530984685615961250
   PubMed Web of Science ®Google Scholar
• BaghaiTCVolzHPMollerHJDrug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilitiesWorld J Biol Psychiatry20067419822217071541
   PubMed Web of Science ®Google Scholar
• MacQueenGMCampbellSMcEwenBSCourse of illness, hippocampal function, and hippocampal volume in major depressionProc Natl Acad Sci U S A200310031387139212552118
   PubMed Web of Science ®Google Scholar
• KaregeFVaudanGSchwaldMPerroudNLa HarpeRNeurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugsBrain Res Mol Brain Res200513612293715893581
   PubMedGoogle Scholar
• SanacoraGZarateCAKrystalJHManjiHKTargeting the glutamatergic system to develop novel, improved therapeutics for mood disordersNat Rev Drug Discov20087542643718425072
   PubMed Web of Science ®Google Scholar
• HaslerGvan der VeenJWTumonisTMayersNShenJDrevetsWCReduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopyArch Gen Psychiatry200764219320017283286
   PubMed Web of Science ®Google Scholar
• LewyAJLeflerBJEmensJSBauerVKThe circadian basis of winter depressionProc Natl Acad Sci U S A2006103197414741916648247
   PubMed Web of Science ®Google Scholar
• BeasleyCLHonerWGBergmannKFaikaiPLutjohannDBayerTAReductions in cholesterol and synaptic markers in association cortex in mood disordersBipol Disord200575449455
   PubMed Web of Science ®Google Scholar
• KennedySEKoeppeRAYoungEAZubeitaJKDysregulation of endogenous opoid emotion regulation circuitry in major depression in womenArch Gen Psychiatry200663111199120817088500
   PubMed Web of Science ®Google Scholar
• JanowskyDSOverstreetDHSoaresJCYoungAHCholinergic-muscarinic dysfunction in mood disordersBipolar Disorders: Basic Mechanisms and Therapeutic Implications2nd edNew York, NYInforma Healthcare2007
   Google Scholar
• SullivanGMMannJJOquendoMALoESCooperTBGormanJMLow cerebrospinal fluid transthyretin levels in depression: Correlations with suicidal ideation and serotonin functionBiol Psychiatry200660550050616487493
   PubMed Web of Science ®Google Scholar
• MilakMSParseyRVKeilpJOquendoMAMaloneKMMannJJNeuroanatomic correlates of psychopathologic components of major depressive disorderArch Gen Psychiatry200562439740815809407
   PubMed Web of Science ®Google Scholar
• NemeroffCBHeimCMThaseMEDifferential response to psycho-therapy versus pharmacotherapy in patients with chronic forms of major depression and childhood traumaProc Natl Acad Sci U S A200310024142931429614615578
   PubMed Web of Science ®Google Scholar
• ImelZEMaltererMBMcKayKMA meta-analysis of psychotherapy and medication in unipolar depression and dysthymiaJ Affect Disord2008110319720618456340
   PubMed Web of Science ®Google Scholar
• KrishanKRRevisiting monoamine oxidase inhibitorsJ Clin Psychiatry200768Suppl 8S35S41
   Google Scholar
• FiedorowiczJGSwartzKLThe role of monoamine oxidase inhibitors in current psychiatric practiceJ Psychiatr Pract200410423924815552546
   PubMedGoogle Scholar
• JessenLKovalickLJAzzaroAJThe selegiline transdermal system (Emsam): A therapeutic option for the treatment of major depressive disorderP T200833421224619750165
   PubMedGoogle Scholar
• GillmanPKTricyclic antidepressant pharmacology and therapeutic drug interactions updatedBr J Pharmacol2007151673774817471183
   PubMed Web of Science ®Google Scholar
• BurkeMJPreskornSHTherapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practiceClin Pharmacokinet199937214716510496302
   PubMed Web of Science ®Google Scholar
• BillupsSJDelateTDuganDEvaluation of risk factors for elevated tricyclic antidepressant plasma concentrationsPharmacoepidemiol Drug Saf200918325325719148878
   PubMed Web of Science ®Google Scholar
• AndersonIMSSRI versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerabilityJ Affect Disord2000581193610760555
   PubMed Web of Science ®Google Scholar
• GervasoniNAurbyJMGex-FarbyMBertschyGBondolfiGIs there a place for tricyclic antidepressant and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?Pharmacol Res200959320220619073260
   PubMed Web of Science ®Google Scholar
• KoenigAMThaseMEFirst-line pharmacotherapies for depression – what is the best choicePol Arch Med Wewn200911978478486
   Web of Science ®Google Scholar
• HiemkeCHartterSPharmacokinetics of selective serotonin reuptake inhibitorsPharmacol Ther2000851112810674711
   PubMed Web of Science ®Google Scholar
• DraperBBermenKTolerability of selective serotonin reuptake inhibitorsDrugs Aging200825650151918540689
   PubMed Web of Science ®Google Scholar
• GreenblattDJvon MoltkeLLSchmiderJHarmatzJSShaderRIInhibition of human cytochrome P4503A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studiesJ Clin Pharmacol19963697927988889899
   PubMed Web of Science ®Google Scholar
• OwensMJKnightDLNemeroffCBSecond-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetineBiol Psychiatry200150534535011543737
   PubMed Web of Science ®Google Scholar
• RaoNThe clinical pharmacokinetics of escitalopramClin Pharmacokinet200746428129017375980
   PubMed Web of Science ®Google Scholar
• SøgaardBMengelHRaoNLarsenFThe pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjectsJ Clin Pharmacol200545121400140616291715
   PubMed Web of Science ®Google Scholar
• SidhuJPriskornMPoulsenMSegonzacAGrollierGLarsenFSteady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humansChirality1997976866929366029
   PubMed Web of Science ®Google Scholar
• RochatBKoselMBossGTestaBGilletMBaumannPStereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidase in human in human liverBiochem Pharmacol199856115239698084
   PubMed Web of Science ®Google Scholar
• KoselMGnerreCVoirolPIn vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparationsMol Psychiatry20027218118811840311
   PubMed Web of Science ®Google Scholar
• GutierrezMMRosenbergJAbramowitzWAn evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavirClin Ther20032541200121012809966
   PubMed Web of Science ®Google Scholar
• MallingDPoulsenMNSogaardBThe effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjectsBr J Clin Pharmacol200560328729016120067
   PubMed Web of Science ®Google Scholar
• JoffePLarsenFSPedersenVLarsen-RingHJørgensen-AaesTSidhuJSingle-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjectsEur J Clin Pharmacol199854392372429681666
   PubMed Web of Science ®Google Scholar
• PericlouARaoNShermanTVenturaDAbramowitzWSingle-dose pharmacokinetics study of escitalopram in adolescents and adultsPharmacotherapy2003231013611362
   Web of Science ®Google Scholar
• CiprianiASantilliCFurukawaTAEscitalopram versus other antidepressive agents for depressionCochrane Database Syst Rev2009CD00653219370639
   PubMed Web of Science ®Google Scholar
• EmslieGJVenturaDKorotzerATourkodimitrisSEscitalopram in the treatment of adolescent depression: A randomized placebo-controlled multisite trialJ Am Acad Child Adolesc Psychiatry200948772172919465881
   PubMed Web of Science ®Google Scholar
• LlorcaPMAzorinJMDespiegelNVerpillatPEfficacy of escitalopram in patients with severe depression: A pooled analysisInt J Clin Pract200559326827515857321
   PubMed Web of Science ®Google Scholar
• SvenssonSMansfieldPREscitalopram: Superior to citalopram or a chiral chimera?Psychother Psychosom2004731101614665791
   PubMed Web of Science ®Google Scholar
• AlexopoulosGSPriviteraWVenturaDBoseAWangQDouble-blind comparison of escitalopram 10 mg/day and optimally-dosed sertraline 50–200 mg/day in the treatment of major depressive disorderPoster presented at the 42nd annual meeting of the American College of NeuropsychopharmacologySan Juan, Puerto RicoDecember 7–11, 2003
   Google Scholar
• KasperSBaldwinDSLonnSLBoulengerJPSuperiority of escitalopram to paroxetine in the treatment of depressionEur Neuropsychopharmacol200919422923719185467
   PubMed Web of Science ®Google Scholar
• MontgomerySAMollerHJIs the significiant superiority of escitalopram compared with other antidepressants clinically relevant?Int Clin Psychopharmacol200924311111819357527
   PubMed Web of Science ®Google Scholar
• BielskiRJVenturaDChangDDA double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorderJ Clin Psychiatry20046591190119615367045
   PubMed Web of Science ®Google Scholar
• KennedySHAndersenHFThaseMEEscitalopram in the treatment of major depressive disorder: A meta-analysisCurr Med Res Opin200925116117519210149
   PubMed Web of Science ®Google Scholar
• KornsteinSGLiDMaoYLarssonSAndersenHFPapakostasGIEscitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trialsCNS Spectr200914632633319668123
   PubMed Web of Science ®Google Scholar
• CiprianiAFurukawaATSalantiGComparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysisLancet2009373966574675819185342
   PubMed Web of Science ®Google Scholar
• MontgomerySAHuusomAKTBothmerJA randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorderNeuropsychobiology2004501576415179022
   PubMed Web of Science ®Google Scholar
• BechPAndersenHFWadeAEffective dose of escitalopram in moderate versus severe DSM-IV major depressionPharmacopsychiatry200639412813416871468
   PubMed Web of Science ®Google Scholar
• BaldwinDSSteinDJDolbergOTBandelowBHow long should a trial of escitalopram treatment be in patients with major depressive disorder? An exploration of a randomized controlled trial databaseHum Psychopharmacol200924426927519334042
   PubMed Web of Science ®Google Scholar
• CroomKFPerryCMPloskerGLMirtazapine: A review of its use in major depression and other psychiatric disordersCNS Drugs200923542745219453203
   PubMed Web of Science ®Google Scholar
• AnttilaSAKLeinonenEVJA review of the pharmacological and clinical profile of mirtazapineCNS Drugs Rev 200173249264
   PubMedGoogle Scholar
• VoortmanGPaanakkerJEBioavability of mirtazapine from Remeron® tablets after single and multiple oral dosingHum Psychopharmacol199510Suppl 2S83S96
   Web of Science ®Google Scholar
• DelbressineLPCMoonenMEGKaspersenFMPharmacokinetics and biotransformation of mirtazapine in human volunteersClin Drug Invest19981514555
   PubMed Web of Science ®Google Scholar
• SpaansEvan den HeuvelMWSchnabelPGConcomitant use of mirtazapine and phenytoin: A drug-drug interaction study in healthy male subjectsEur J Clin Pharmacol200258642342912242602
   PubMed Web of Science ®Google Scholar
• RuweFJSmuldersRAKleijnHJMirtazapine and paroxetine: A drug-drug interaction study in healthy subjectsHum Psychopharmacol200116644945912404553
   PubMed Web of Science ®Google Scholar
• AnttilaAKRasanenLLeinonenEVFluvoxamine augmentation increases serum mirtazapine concentrations three- to four-foldAnn Pharmacother200135101221122311675851
   PubMed Web of Science ®Google Scholar
• SitsenJMMarisFATimmerCJConcomitant use of mirtazapine and cimetidine: A drug-drug interaction study in healthy male subjectsEur J Clin Pharmacol200056538939411009047
   PubMed Web of Science ®Google Scholar
• GrasmäderKVerwohltPLKühnKUPopulation pharmacokinetic analysis of mirtazapineEur J Clin Pharmacol200460747348015289959
   PubMed Web of Science ®Google Scholar
• BrockmöllerJMeinekeIKirchheinerJPharmacokinetics of mirtazapine: Enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effectsClin Pharmacol Ther200781569970717329996
   PubMed Web of Science ®Google Scholar
• TimmerCJLohmannAAMMinkCPAPharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tabletsHum Psychopharmacol199510Suppl 2S97S106
   Web of Science ®Google Scholar
• LindABReisBengtssonFSteady-state concetration of mirtazapine, N- desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviourClin Pharmacokinet2009481637019071885
   PubMed Web of Science ®Google Scholar
• BengtssonFHöglundPTimmerCHegbrantJMirtazapine oral single dose kinetics in patients with different degrees of renal failureHum Psychopharmacol1998135357365
   Web of Science ®Google Scholar
• Organon USA IncRemeron (mirtazapine) tablets: US prescribing information (online) Avaliable from URL:http://www.organon.comAccessed May 5, 2010
   Google Scholar
• MontgomerySAReimitzPEZivkovMMirtazapine versus amitriptyline in long-term treatment of depression: A double-blind placebo-controlled studyInt Clin Psychopharmacol199813263739669186
   PubMed Web of Science ®Google Scholar
• WatanabeNOmoriIMNakagawaAMirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysisJ Clin Psychiatry20086991404141519193341
   PubMed Web of Science ®Google Scholar
• GuelfiJDAnsseauMTimmermanLKørsgaardSMirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic featuresJ Clin Psychopharmacol200121442543111476127
   PubMed Web of Science ®Google Scholar
• PapakostasGIHombergerCHFavaMA meta-analysis of clinical trails comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorderJ Psychopharmacol200822884384818308801
   PubMed Web of Science ®Google Scholar
• StahlSMPradkoJFHaightBRModellJGRockettCBLearned- CoughlinSA review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitorPrim Care Companion J Clin Psychiatry20046415916615361919
   PubMedGoogle Scholar
• DhillonSYangLPHCurranMPBupropion: A review of its use in the managment of major depressive disorderDrugs200868565368918370448
   PubMed Web of Science ®Google Scholar
• JeffersonJWPradkoJFMuirKTBupropion for major depressive disorder: Pharmacokinetic and formulation considerationsClin Ther200527111685169516368442
   PubMed Web of Science ®Google Scholar
• RotzingerSBourinMAkimotoYCouttsRTBakerGBMetabolism of some “second” and “fourth” generation antidepressants: Iprindole, viloxazine, bupropion, mianserin, maprotilin, trazodone, nefazodone, and venlafaxineCell Mol Neurobiol199919442744210379419
   PubMed Web of Science ®Google Scholar
• HesseLMVenkatakrishnanKCourtMHCYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressantsDrug Metab Dispos20028101176118310997936
   PubMedGoogle Scholar
• KirchheinerJKleinCMeinekeIBupropion and 4-O-Hbupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6Pharmacogenetics2003131061962614515060
   PubMedGoogle Scholar
• KetterTAJenkinsJBSchroederDHCarbamazepine but not valproate induces bupropion metabolismJ Clin Psychopharmacol19951553273338830063
   PubMed Web of Science ®Google Scholar
• HogelandGWSwindellsSMcNabbJCKashubaADYeeGCLindleyCMLopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjectsClin Pharmacol Ther2007811697517186001
   PubMed Web of Science ®Google Scholar
• KennedySHMcCannSMMasellisMCombining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effectsJ Clin Psychiatry200263318118611926715
   PubMed Web of Science ®Google Scholar
• McCollumDLGreeneJLMcGuireDKSevere sinus bradycardia after initiation of bupropion therapy: A probable drug-drug interaction with metoprololCardiovasc Drugs Ther200418432933015367832
   PubMed Web of Science ®Google Scholar
• StewartJJBerkelHJParishRCSingle-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and genderJ Clin Pharmacol200141777077811452710
   PubMed Web of Science ®Google Scholar
• HsyuPHSinghAGiargiariTDDunnJAAscherJAJohnstonJAPharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokersJ Clin Pharmacol19973787377439378846
   PubMed Web of Science ®Google Scholar
• SweetRAPollockBGKirshnerMWrightBAltieriLPDeVaneCLPharmacokinetics of single- and multiple-dose bupropion in elderly patients with depressionJ Clin Pharmacol19953598768848786247
   PubMed Web of Science ®Google Scholar
• TurpeinenMKoivuviitaNTolonenAEffect of renal impairment on the pharmacokinetics of bupropion and its metabolitesBr J Clin Pharmacol200764216517317335546
   PubMed Web of Science ®Google Scholar
• ReimherrFWCunninghamLABateySRJohnstonJAAscherJAA multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatientsClin Ther19982035055169663366
   PubMed Web of Science ®Google Scholar
• JeffersonJWRushAJNelsonJCExtended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: Findings from a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200667686587316848645
   PubMed Web of Science ®Google Scholar
• MascoHLKievAHollomanLCBateySRJohnstonJALineberryCGSafety and efficacy of bupropion and nortriptyline in outpatients with depressionCurr Ther Res1994557851863
   Web of Science ®Google Scholar
• MendelsJAminMMChouinardGA comparative study of bupropion and amitriptyline in depressed outpatientsJ Clin Psychiatry1983445 Pt 21181206406439
   PubMed Web of Science ®Google Scholar
• FeighnerJPGardnerEAJohnstonJADouble-blind comparison of bupropion and fluoxetine in depressedoutpatients J Clin Psychiatry 1991528329335
   Web of Science ®Google Scholar
• ColemanCCKingBRBolden-WatsonCA placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetineClin Ther20012371040105811519769
   PubMed Web of Science ®Google Scholar
• WeihsKLSettleEJrBateySRHouserTLDonahueRMAscherJABupropion sustained release versus paroxetine for the treatment of depression in the elderlyJ Clin Psychiatry200061319620210817105
   PubMed Web of Science ®Google Scholar
• ClaytonAHCroftHAHorriganJPBupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in two randomized, double-blind, placebo-controlled studiesJ Clin Psychiatry200667573674616841623
   PubMed Web of Science ®Google Scholar
• HewettKChrzanowskiWSchmitzMEight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XRJ Psychopharmacol200923553153818635695
   PubMed Web of Science ®Google Scholar
• ThaseMEClaytonAHHaightBRThompsonAHModellJGJohnstonJAA double-blind comparison between bupropion XR and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerabilityJ Clin Psychopharmacol200626548248816974189
   PubMed Web of Science ®Google Scholar
• RushAJTrivediMHWisniewskiSRBupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depressionN Engl J Med2006354121231124216554525
   PubMed Web of Science ®Google Scholar
• TrivediMHFavaMWisniewskiSRMedication augmentation after the failure of SSRIs for depressionN Eng J Med20063541212431252
   PubMed Web of Science ®Google Scholar
• RoseboomPHKalinNHNeuropharmacology of venlafaxineDepress Anxiety200012Suppl 1S20S29
   Web of Science ®Google Scholar
• TroySMParkerVDFruncilloRJChiangSTThe pharmacokinetics of venlafaxine when given in twice-daily regimenJ Clin Pharmacol19953544044097650231
   PubMed Web of Science ®Google Scholar
• TroySMDileaCMartinPTLeisterCAFruncilloRJChiangSTPharmacokinetics of once-daily venlafaxine extended release in healthy volunteersCurr Ther Res1997568504514
   Web of Science ®Google Scholar
• EreshefskyLDuganDReview of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxineDepress Anxiety200012Suppl 1S30S44
   PubMed Web of Science ®Google Scholar
• IlettKFKristensenJHHackettPPaechMKohanRRamponoJDistribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infantsBr J Clin Pharmacol2002531172211849190
   PubMed Web of Science ®Google Scholar
• OttonSVBallSECheungSWInabaTRudolphRLSellersEMVenlafaxine oxidation in vitro is catalysed by CYP2D6Br J Clin Pharmacol19964121491568838442
   PubMed Web of Science ®Google Scholar
• FogelmanSMSchmiderJVenkatakrishnanKO- and N- demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressantsNeuropsychopharmacology199920548049010192828
   PubMed Web of Science ®Google Scholar
• PreskornSPatronevaASilmanHComparation of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizersJ Clin Psychopharmacol2009291394319142106
   PubMed Web of Science ®Google Scholar
• PreskornSHNicholsAIPaulJPatranevaALHelznerECGuico-PabiaCJEffect of desvenlafaxine on the cytochrome P450 2D6 enzyme systemJ Psychiatr Pract200814636837819057238
   PubMed Web of Science ®Google Scholar
• AlbersLJReistCVuRLEffect of venlafaxine on imipramine metabolismPsychiatry Res200096323524311084219
   PubMed Web of Science ®Google Scholar
• AmchinJZarycranskiWTaylorKPAlbanoDKlockowskiPMEffect of venlafaxine on the pharmacokinetics of risperidoneJ Clin Pharmacol199939329730910073330
   PubMed Web of Science ®Google Scholar
• LessardEYessineMAHamelienBADiphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humansJ Clin Psychopharmacol200121217518411270914
   PubMed Web of Science ®Google Scholar
• TroySMSchultzRWParkerVDChiangSTBlumRAThe effect of renal diseaase on the disposition of venlafaxineClin Pharmacol Ther199456114218033490
   PubMed Web of Science ®Google Scholar
• HowellSRHusbandsGEMScatinaJASisenwineSFMetabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and manXenobiotica1993234349598337893
   PubMed Web of Science ®Google Scholar
• KlamerusKJParkerVDRudolphRLDerivanATChiangSTEffects of age and gender on venlafaxine pharmacokineticsPharmacotherapy1996165915238888087
   PubMed Web of Science ®Google Scholar
• ThaseMEEfficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study GroupJ Clin Psychiatry19975893933989378690
   PubMed Web of Science ®Google Scholar
• BauerMTharmanathanPVolzHPMoellerHJFreemantleNThe effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depressionEur Arch Psychiatry Clin Neurosci2009259317218519165525
   PubMed Web of Science ®Google Scholar
• SirAD’SouzaRFUguzSRandomized trial of sertraline versus venlafaxine XR in major depression: Efficacy and discontinuation symptomsJ Clin Psychiatry200566101312132016259546
   PubMed Web of Science ®Google Scholar
• ThaseMEntsuahARudolphRRemission rates during treatment with venlafaxine or selective serotonine reuptake inhibitorsBr J Psychiatry2001178323424111230034
   PubMed Web of Science ®Google Scholar
• ThaseMEEntsuahRAhmedSSloanDMNemeroffCBMeta-analysis of randomized controlled trials comparing venlafaxine and SSRIs: The evidence revisitedPresented at the 2005 annual meeting of the American Psychiatric AssociationAtlanta, GeorgiaMay 21–26, 2005
   Google Scholar
• AndersonIMMeta-analytical studies of new antidepressantsBr Med Bull200157116117811719915
   PubMed Web of Science ®Google Scholar
• HansenRAGartlehnerGLohrKNGaynesBNCareyTSEfficacy and safety of second-generation antidepressants in the treatment of major depressive disorderAnn Intern Med2005143641542616172440
   PubMed Web of Science ®Google Scholar
• Lenox-SmithAGreenstreetLBurslemKKnightCCost effectivness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UKClin Drug Investig2009293173184
   Web of Science ®Google Scholar
• LiebowitzMRManleyALPadmanabhanSKGangulyRTummalaRTourianKAEfficacy, safety, and tolerability of desvenlafaxine 50 mg/ day and 100 mg/day in outpatients with major depressive disorderCurr Med Res Opin20082471877189018507895
   PubMed Web of Science ®Google Scholar
• FeighnerJPThe role of venlafaxine in rational antidepressant therapyJ Clin Psychiatry199455Suppl A62687961545
   PubMed Web of Science ®Google Scholar
• HaddadPMAntidepressant discontinuation syndromesDrug Saf200124318319711347722
   PubMed Web of Science ®Google Scholar
• BuckleyNAMcManusPRFatal toxicity of serotoninergic and other antidepressant drugs: Analysis of United Kingdom mortality dataBMJ200232573761332133312468481
   PubMed Web of Science ®Google Scholar
• ThaseMESheltonRCKhanATreatment with venlafaxine extended- release after SSRI nonresponse or intolerance: A randomized comparison of standard- and higher-dosing strategiesJ Clin Psychopharmacol200626325025816702889
   PubMed Web of Science ®Google Scholar
• PaeCUDesvenlafaxine: A new antidepressant or just another oneExpert Opin Pharmacother200910587588719351235
   PubMed Web of Science ®Google Scholar
• ClaytoneAHKornsteinSGRosasGGuico-PabiaTourianKAAn integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorderCNS Spectr200914418319519407730
   PubMed Web of Science ®Google Scholar
• GuelfiJDWhiteCHackettDGuichouxJYMagniGEffectiveness of venlafaxine in patients hospitalized for major depression and melancholiaJ Clin Psychiatry199556104504587559370
   PubMed Web of Science ®Google Scholar
• BymasterFPDreshfield-AhmadLJThrelkeldPGComparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptorsNeuropsychopharmacology200125687188011750180
   PubMed Web of Science ®Google Scholar
• ZhaoRKChengGTangJSongJPengWXPharmacokinetics of duloxetine hydrocloride enteric-coated tablets in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose studyClin Ther20093151022103619539103
   PubMed Web of Science ®Google Scholar
• SkinnerMHSkerjanecASegerMHewittRThe effect of food and bedtime administration on duloxetine pharmacokineticsClin Pharmacol Ther2000672129 Abstract
   Web of Science ®Google Scholar
• SharmaAGoldbergMJCerimeleBJPharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitorJ Clin Pharmacol200040216116710664922
   PubMed Web of Science ®Google Scholar
• FramptonJEPloskerGLDuloxetine: A review of its use in the treatment of major depressive disorderCNS Drugs200721758160917579500
   PubMed Web of Science ®Google Scholar
• LantzRJGillespieTARashTJMetabolism, exretion, and pharmacokinetics of duloxetine in healthy human subjectsDrug Metab Dispos 20033191142115012920170
   PubMed Web of Science ®Google Scholar
• LoboEDBergstromRFReddySIn vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetineClin Pharmacokinet200847319120218307373
   PubMed Web of Science ®Google Scholar
• HunzikerMESuehsBTBettingerTLCrismonMLDuloxetine hydrochloride: A new dual-acting medication for the treatment of major depressive disorderClin Ther20052781126114316199241
   PubMed Web of Science ®Google Scholar
• SkinnerMHKuanHYPanADuloxetine is both an inhibitor and a substrate of cytochrome P450 2D6 in healthy volunteersClin Pharmacol Ther200373317017712621382
   PubMed Web of Science ®Google Scholar
• LoboEDQuinlanTO’BrienLPat KnadlerMHeathmanMPopulation pharmacokinetics of orally administered duloxetine in patientsClin Pharmacokinet200948318919719385712
   PubMed Web of Science ®Google Scholar
• SuriAReddySGonzalesDRKnadlerMPSkinnerMDuloxetine pharmacokinetics in cirrhotics compared with healthy subjectsInt J Clin Pharmacol Ther2005432788415726876
   PubMed Web of Science ®Google Scholar
• BrannanSKMallinckrodtCHBrownEBWohlreichMMWatkinJJGSchatzbergAFDuloxetine 60 mg once daily in the treatment of painful physical symptoms in patients with major depressive disorderJ Psychiatr Res2005391435315504423
   PubMed Web of Science ®Google Scholar
• SpielmansGIDuloxetine does not relieve painful physical symptoms in depression: A meta-analysisPsychother Psychosom2008771121618087203
   PubMed Web of Science ®Google Scholar
• ThaseMEPritchettYLOssannaMJSwindleRWXuJDetkeMJEfficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorderJ Clin Psychopharmacol200727667267618004135
   PubMed Web of Science ®Google Scholar
• PerahiaDGPritchettYLKajdaszDKA randomized, double blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorderJ Psychiatr Res2008421223417445831
   PubMed Web of Science ®Google Scholar
• GuptaSNihalaniNMasandPDuloxetine: Review of its pharmacology, and therapeutic use in depression and other psychiatric disordersAnn Clin Psychiatry200719212513217612852
   PubMedGoogle Scholar
• WadeAGembertKFloreaIA comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorderCurr Med Res Opin20072371605161417559755
   PubMed Web of Science ®Google Scholar
• NierenbergAAGreistJHMallinckrodtCHDuloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: Onset of antidepressant action, a non-inferiority studyCurr Med Res Opin200723240141617288694
   PubMed Web of Science ®Google Scholar
• MallinckrodtCHPrakashAAndornACWatkinJGWohlreichMMDuloxetine for the treatment of major depressive disorder: A closer look at efficacy and safety data across the approved dose rangeJ Psychiatr Res200640433734816271726
   PubMed Web of Science ®Google Scholar
• WiseTNPerahiaDGPangalloBALosinWGWiltseCGEffects of the antidepressants duloxetine on body weight: Analysis of 10 clinical studiesPrim Care Companion J Clin Psychiatry20068526927817235383
   PubMedGoogle Scholar
• ThaseMETranPVWiltseCPangalloBAMallinckrodtCDetkeMJCardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrineJ Clin Psychopharmacol200525213214015738744
   PubMed Web of Science ®Google Scholar
• DelgadoPLBrannanSKMallinckrodtCHSexual functioning assessed in 4 double-blind placebo- and paroxetine- controlled trials of duloxetine for major depressive disorderJ Clin Psychiatry200566668669215960560
   PubMed Web of Science ®Google Scholar
• NelsonJCLu PritchettYMartynovOYuJYMallinckrodtCHDetkeMJThe safety and tolerability of duloxetine compared with paroxetine and placebo: A pooled analysis of 4 clinical trialsPrim Care Companion J Clin Psychiatry20068421221916964316
   PubMedGoogle Scholar
• SpencerCMWildeMIMilnacipran: A review of its use in depressionDrugs19985634054279777315
   PubMed Web of Science ®Google Scholar
• VaishnaviSNNemeroffCBPlottSJRaoSGKranzlerJOwensMJMilnacipran: A comparative analysis of human monoamine uptake and transporter binding affinityBiol Psychiatry200455332032214744476
   PubMed Web of Science ®Google Scholar
• HindmarchIRigneyUStanleyNBrileyMPharmacodynamics of milnacipran in young and elderly volunteersBr J Clin Pharmacol200049211812510671905
   PubMed Web of Science ®Google Scholar
• CadaDJLevienTLBakerDEMilnacipranHosp Pharm2009447604615
   Google Scholar
• PuozzoCLensSRehCLack of interactions of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressantsClin Pharmacokinet200544997798816122284
   PubMed Web of Science ®Google Scholar
• PuozzoCLeonardBEPharmacokinetics of milnacipran in comparison with other antidepressantsInt Clin Psychopharmacol199611Suppl 4S15S27
   PubMed Web of Science ®Google Scholar
• PuozzoCHermannPChassardDLack of pharmacokinetic interaction when switching from fluoxetine to milnacipranInt Clin Psychopharmacol200621315315816528137
   PubMed Web of Science ®Google Scholar
• LecrubierYPletanYSollesATournouxAMagneVClinical efficacy of milnacipran: Placebo-controlled trialsInt Clin Psychopharmacol199611Suppl 4S29S33
   PubMed Web of Science ®Google Scholar
• MacherJPSichelJPSerreCVon FrenckellRHuckJCDemarezJPDouble-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disordersNeuropsychobiology198922277822701744
   PubMed Web of Science ®Google Scholar
• PapakostasGIFavaMA meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorderEur Neuropsychopharmacol2007171323616762534
   PubMed Web of Science ®Google Scholar
• NakagawaAWatanabeNOmoriIMEfficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: A systemic review and meta-analysisCNS Drugs200822758760218547127
   PubMed Web of Science ®Google Scholar
• WongEHFSondersMSAmaraSGReboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitorBiol Psychiatry200047981882910812041
   PubMed Web of Science ®Google Scholar
• FleishakerJCClinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depressionClin Pharmacokinet200039641342711192474
   PubMed Web of Science ®Google Scholar
• EdwardsDMPellizzioniCBreuelHPPharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein bindingBiopharm Drug Dispos19951664434607579027
   PubMed Web of Science ®Google Scholar
• FleishakerJCMucciMPellizzioniCPoggesiIAbsolute bioavailability of reboxetine enantiomers and effects of gender on pharmacokineticsBiopharm Drug Dispos1999201535710086838
   PubMed Web of Science ®Google Scholar
• PellizzioniCBenedetti StrolinMPoggesiIFrigerioEToonSLangleySJPharmacokinetics of reboxetine in healthy volunteers: Relative bioavailability and food effectPharmacol Res199531Suppl 1S41
   Google Scholar
• WienkersLCAllieviCHauerMJWynaldaMACytochrome P450- mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomesDrug Metab Dispos199927111334134010534319
   PubMed Web of Science ®Google Scholar
• HendershotPEFleishakerJCLinKMNuccioIDPolandREPharmacokinetics of reboxetine in healthy volunteers with different ethnic descentsPsychopharmacology2001155214815311401003
   PubMed Web of Science ®Google Scholar
• PoggesiIPellizzoniCFleishakerJCPharmacokinetics of reboxetine in elderly patients with depressive disordersInt J Clin Pharmacol Ther200038525425910839469
   PubMed Web of Science ®Google Scholar
• BergmannJFLaneuryJPDuchenePFleishakerJCHouinGSégrestaaJMPharmacokinetics of reboxetine in healthy, elderly volunteersEur J Drug Metab Pharmacokinet20002534195198
   Web of Science ®Google Scholar
• CoulombFDucretFLaneuryJPPharmacokinetics of single-dose reboxetine in volunteers with renal insufficiencyJ Clin Pharmacol200040548248710806601
   PubMed Web of Science ®Google Scholar
• TranALaneuryJPDuchênePPharmacokinetics of reboxetine in volunteers with hepatic impairmentClin Drug Invest2000196473477
   Web of Science ®Google Scholar
• MontgomerySFergusonJMSchwartzGEThe antidepressant efficacy of reboxetine in patients with severe depressionJ Clin Psychopharmacol2003231455012544375
   PubMed Web of Science ®Google Scholar
• VersianiMMehilaneLGasznerPArnaud-CastiglioniRReboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorderJ Clin Psychiatry199960640040610401920
   PubMed Web of Science ®Google Scholar
• BerzewskiHVan MoffaertMGagianoCAEfficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodesEur Neuropsychopharmacol19977Suppl 1S37S479169309
   PubMed Web of Science ®Google Scholar
• KatonaCBercoffEChiuETackPVersianiMWoelkHReboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomized trialJ Affect Disord19995523203213
   Web of Science ®Google Scholar
• MontgomerySAChairman’s overview. The place of reboxetine in antidepressant therapyJ Clin Psychiatry199859Suppl 14S26S29
   PubMed Web of Science ®Google Scholar
• MassanaJMollerHJBurrowsSGMontenegroRMReboxetine: A double-blind comparison with fluoxetine in major depressive disorderInt Clin Psychopharmacol1999142738010220121
   PubMed Web of Science ®Google Scholar
• AndreoliVCaillardVDeoRSRybakowskiJKVersianiMReboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in treatment of depressionJ Clin Psychopharmacol200222439339912172339
   PubMed Web of Science ®Google Scholar
• KasperSHamonMBeyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of actionWorld J Biol Psychiatry200910211712619255935
   PubMed Web of Science ®Google Scholar
• ZupancicMGuilleminaultCAgomelatine: A preliminary review of a new antidepressantCNS Drugs2006201298199217140278
   PubMed Web of Science ®Google Scholar
• MillanMJGobertALejeuneFThe novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine (2C) receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathwaysJ Pharmacol Exp Ther2003306395496412750432
   PubMed Web of Science ®Google Scholar
• ServierValdoxanSummary of product characteristics Available from: http://www.servier.co.uk/pdfs/Valdoxan_SPC.pdfAccessed on 2010 May 5
   Google Scholar
• KennedySHEmsleyRPlacebo-controlled trial of agomelatine in the treatment of major depressive disorderEur Neuropsychopharmacol20061629310016249073
   PubMed Web of Science ®Google Scholar
• LooHHaleAD’haenenHDetermination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: A placebocontrolled dose range studyInt Clin Psychopharmacol200217523924712177586
   PubMed Web of Science ®Google Scholar
• MontgomerySAKasperSSevere depression and antidepressants: Focus on a pooled analysis of placebo-controlled studies on agomelatineInt Clin Psychopharmacol200722528329117690597
   PubMed Web of Science ®Google Scholar
• KennedySHSexual function in remitted depressed patients following agomelatine and venlafaxine XR treatmentEur Neuropsychopharmacol200515Suppl 3 Abstr S440
   Google Scholar
• GuilleminaultCEfficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorderEur Neuropsychopharmacol200515Suppl 3S419S420 Abstract
   Google Scholar
• MongomerySAKennedySHBurrowsGDLejoyeuxMHindmarchIAbsence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation studyInt Clin Psychopharmacol200419527128015289700
   PubMed Web of Science ®Google Scholar
• WeberJLyseng-WilliamsonKAScottLJAripiprazole: In major depressive disorderCNS Drugs2008221080781318788833
   PubMed Web of Science ®Google Scholar
• BermanRMMarcusRNSwaninkRThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768684385317592907
   PubMed Web of Science ®Google Scholar
• MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200828215616518344725
   PubMed Web of Science ®Google Scholar
• CarrollBJAripiprazole in refractory depression?J Clin Psychopharmacol2009291909119142117
   PubMed Web of Science ®Google Scholar
• TsaiACUnclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder. Comments on article by Marcus et alJ Clin Psychopharmacol2009291919219142118
   PubMed Web of Science ®Google Scholar
• DawsonLAWatsonJMVilazodone: A 5-HT1A receptor agonist/ serotonin transporter inhibitor for the treatment of affective disordersCNS Neurosci Ther200915210711719499624
   PubMed Web of Science ®Google Scholar
• RickelsKAthanasiouMRobinsonDSGibertiniMWhalenHReedCREvidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, doubleblind, placebo-controlled trialJ Clin Psychiatry200970332633319284933
   PubMed Web of Science ®Google Scholar
• MillanMJDual- and triple-acting agents for treating core and comorbid symptoms of major depression: Novel concepts, new drugsNeurotherapeutics200961537719110199
   PubMed Web of Science ®Google Scholar
• SenSSanacoraGMajor depression: Emerging therapeuticsMt Sinai J Med200875320422518704976
   PubMedGoogle Scholar
• NeuroSearch announces the results of Phase II proof of concept studies with NS2359 in depression Available from: https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=313018&messageId=372903Accessed on 2010 May 5
   Google Scholar
• AndrésJIAlcazarJAlonsoJMTricyclic isoxazolines: Identification of R226161 as a new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonismBioorg Med Chem200715113649366017407815
   PubMed Web of Science ®Google Scholar
• GobertACussacDLejeuneFThe novel antidepressant, S35966, is a mixed serotonin and noradrenaline reuptake inhibitor and an antagonist at α2-adrenoceptorsEur Neuropsychopharmacol200212Suppl 3S248
   Google Scholar
• DemyttenaereKCompliance and acceptance in antidepressant treatmentInt J Psych Clin Pract20015Suppl 1S29S35
   Web of Science ®Google Scholar
• SawadaNUchidaHSuzukiTPersistance and compliance to antidepressant treatment in patients with depression: A chart reviewBMC Psychiatry 200993819531229
   PubMed Web of Science ®Google Scholar
• RooseSPCompliance: The impact of adverse events and tolerability on the physician’s treatment decisionsEur Neuropsychopharm200313Suppl 3S85S92
   PubMed Web of Science ®Google Scholar
• HaslamCBrownSAtkinsonSHaslamRPatients’ experiences of medication for anxiety and depression: Effects on working lifeFamily Practice200421220421215020393
   PubMed Web of Science ®Google Scholar